MedTrace Logo

Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours

NCT02016391 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-12-17

No results posted yet for this study

Summary

The purpose of he study is to evaluate effects of dexmedetomidine on pain during radiofrequency ablation of liver and kidney tumours.

Conditions

  • Cancer of Kidney and Renal Pelvis
  • Cancer of Liver

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure

Sponsors & Collaborators

  • Uppsala University Hospital

    lead OTHER

Principal Investigators

  • Egidijus Semenas, MD, PhD · Uppsala University Hospital, Uppsala, Sweden

  • Mats Eriksson, MD, PhD · Uppsala University Hospital, Uppsala, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02016391 on ClinicalTrials.gov